On Tuesday, Tactile Systems Technology (NASDAQ:TCMD) was downgraded from Buy to Neutral by BTIG following the company's third-quarter results, which fell short of expectations.
Tactile Systems reported quarterly revenue of approximately $73.1 million, missing both BTIG's and the Street's estimates of $76.3 million and $76.0 million, respectively. The company's Medicare business saw a significant year-over-year decline of about 41.5%, which was a sharper drop than in the previous quarter.
The reduced performance has led Tactile Systems to lower its full-year 2024 guidance for the second time this year, now anticipating revenues between $292 million and $295 million. This represents a growth rate of 6% to 8% year-over-year, adjusted down from the previously estimated range of $293 million to $298 million.
Despite the company's shares being considered inexpensive at approximately 0.9x next twelve months' enterprise value/sales, and the announcement of a $30 million share buyback, concerns persist regarding the impact of documentation requirements on sales force productivity and growth across other payer channels.
BTIG expressed concerns that the current challenges may continue into the next few quarters, despite Tactile Systems' efforts to address the issues. The firm also noted that with fiscal year 2025 revenue expectations of around 12% year-over-year growth compared to the roughly 7% Tactile Systems is on track for fiscal year 2024, there are insufficient drivers to reaccelerate growth in the first half of 2025.
The analyst suggests that expectations may need to be recalibrated before any potential improvement in the stock's performance.
The report concludes with a note on Tactile Systems' operational management, acknowledging that the company is handling its profit and loss statement with greater efficiency. However, BTIG ultimately indicates that an improvement in top-line revenue is necessary for investor interest to be reignited.
In other recent news, Tactile Medical (TASE:PMCN) is enhancing technology tools and modernizing workflows to address challenges in sales rep productivity. The company also anticipates improved sales following the shift to the National Coverage Determination policy, which allows for more interpretation by Medicare Administrative Contractors.
Lastly, the launch of the new Nimbl device and strong clinical trial results for Flexitouch are expected to contribute to future growth.
InvestingPro Insights
Despite the recent downgrade and challenges faced by Tactile Systems Technology (NASDAQ:TCMD), InvestingPro data reveals some interesting insights that may provide a more nuanced view of the company's financial position.
According to InvestingPro, TCMD's revenue for the last twelve months as of Q2 2024 stands at $281.54 million, with a revenue growth of 5.71% over the same period. This aligns with the company's revised full-year guidance mentioned in the article, suggesting a growth rate of 6% to 8% year-over-year.
An InvestingPro Tip highlights that TCMD has been profitable over the last twelve months, with a P/E ratio of 12.32. This profitability, combined with the company's moderate debt level, as noted in another InvestingPro Tip, could provide some stability during this challenging period.
Interestingly, despite the recent downgrade, TCMD has shown a strong return over the last three months, with InvestingPro data indicating a 30.94% price total return. This performance, coupled with analysts' predictions that the company will remain profitable this year, as suggested by an InvestingPro Tip, may offer a glimmer of hope for investors.
For readers seeking a more comprehensive analysis, InvestingPro offers additional tips and insights beyond those mentioned here. The platform currently lists 7 more tips for TCMD, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.